About Bugworks Research
Bugworks Research is a Healthcare company based in Saratoga (United States) founded in 2014 by Santanu Datta and Anand Anandkumar. Drugs for antibiotic-resistant infections and cancer are developed. Bugworks Research has raised $42.89 million across 15 funding rounds from investors including NIH, Baxter and 3one4 Capital. Its chief executive, as recorded, is Anand Anandkumar. Its Indian entity Bugworks Research India Private Limited reported revenue of ₹25.18 Cr. Bugworks Research offers products and services including Antibacterial Agents and Oncology Therapeutics. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Bugworks Research was founded in 2014 in Saratoga, United States, within the biotechnology sector. Therapeutics targeting antibiotic-resistant bacterial infections and cancer are developed using the Microbial Platform (BMP), which models biofilm formation and bacterial behavior. A lead Gyrase-topoisomerase inhibitor is advanced for intravenous and oral treatments of multi-drug resistant infections, with mechanisms that inhibit two replication targets and circumvent bacterial efflux resistance.
- Headquarters Saratoga, United States
- Founders Santanu Datta, Anand Anandkumar
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bugworksresearch.com
- Social LinkedIn X
- Legal Name Bugworks Research India Private Limited
- Date of Incorporation 04 Feb, 2014
- Jurisdiction Bangalore, Karnataka, India
- Indian entity revenue₹25.18 Cr
FY 2025 · -12% YoY
- Indian entity net profit₹2.46 Cr
FY 2025 · 10% margin
- Indian entity EBITDA₹3.80 Cr
FY 2025 · 15% margin
- Total Equity Funding$42.89M (USD)
in 15 rounds
- Latest Funding Round$6.78M (USD), Series B
Feb 2024
- InvestorsNIH
& 19 more
Associated legal entities of Bugworks Research
Bugworks Research operates through Bugworks Research India Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Bugworks Research India Private Limited CIN U73100KA2014PTC073409 | Active | 04 Feb 2014 | Bangalore, Karnataka | ₹25.2 Cr | 30 | 3 | View details |
Products & Services of Bugworks Research
Bugworks Research offers a comprehensive portfolio of products and services, including Antibacterial Agents and Oncology Therapeutics.
Novel small molecules targeting multidrug-resistant infections.
Small molecules for hypoxic and refractory solid tumors.
Funding Insights of Bugworks Research
Bugworks Research has successfully raised a total of $42.89M across 15 strategic funding rounds. The most recent funding activity was a Series B round of $6.78 million completed in February 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $42.89M
- Total Rounds 15
- Last Round Series B — $6.78M
- Investors Count 20
Latest 10 of 15 funding rounds of Bugworks Research with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2024 | $6.78M | Series B | – | – | – |
| Dec 2021 | $18M | Series B | – | Lightrock India | |
| Apr 2021 | Grant | – | – | ||
| Apr 2020 | $7.5M | Series B | – | UTEC, Global Brain | – |
| Aug 2018 | $9M | Series A | – | UTEC | |
| Jun 2018 | $6.2M | Grant | – | – | |
| Jul 2017 | Grant | – | – | ||
| Jun 2016 | Seed | – | – | ||
| Jun 2016 | Grant | – | – | ||
| Nov 2015 | $1.61M | Seed | – | – | – |
20 investors in total: 17 institutional and 3 angel.
Investors in Bugworks Research
Bugworks Research has secured backing from 20 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include NIH, Baxter and 3one4 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investments in technology sectors like SaaS and Fintech in India. | 2016 | 3one4capital.com | Bengaluru, India | |
Global Brain is recognized as a venture capital firm supporting startups. | globalbrains.com | Shibuya, Japan | ||
Seed and Early stage VC firm investing in Japan | ut-ec.co.jp | Tokyo, Japan | ||
| acquipharmaholdings.tcc.mode | ||||
Private equity firm focused on healthcare, renewable energy, education, and other sectors | 2019 | lr-india.com | Bengaluru, India | |
Business incubation services are provided across multiple sectors. | birac.nic.in | Delhi, India | ||
Provides comprehensive end-to-end logistics services for efficient operations. | 1999 | im-holdings.com | Singapore, Singapore | |
Offers comprehensive services for residential and commercial property development. | 2006 | featherlitedevelopers.com | Bengaluru, India | |
| dtra.mil | ||||
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States |
Investor details for Bugworks Research
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Bugworks Research India Private Limited (Bugworks Research)
Bugworks Research India Private Limited is the primary company behind Bugworks Research. The board of Bugworks Research India Private Limited currently have 3 directors; the longest-serving is Balasubramanian Venkataraman, appointed in 2014. 6 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Balasubramanian Venkataraman DIN 05102736 | Whole-time director | 11 Sep 2014 | 12 yrs 1 mo | Bugworks Research India Private Limited |
| Vasanthi Ramachandran DIN 09607559 | Director | 26 May 2022 | 4 yrs 5 mo | Bugworks Research India Private Limited |
| Shahul Hameed Peer Mohamed DIN 09607578 | Director | 26 May 2022 | 4 yrs 5 mo | Bugworks Research India Private Limited |
People of Bugworks Research
27 people are tracked at Bugworks Research (9 in leadership, 7 in board & advisors, 11 in team).
| Name | Role | Group |
|---|---|---|
Santanu Datta | Co-Founder | Leadership |
Anand Anandkumar | Co-Founder & CEO | Leadership |
John F. Tomayko | CMO | Leadership |
| VP, Collaborations | Leadership | |
Balasubramanian V | COO | Leadership |
Ranga Rao | Associate Director | Leadership |
pradeep fernandes | Head Corp, Strategy and Biz Dev | Leadership |
Sreenath Rajagopal | Assistant Director- IT And Business Development | Leadership |
Leela Maitreyi | Director, Global Alliances & BD | Leadership |
Vis Niranjan | Advisor | Board & advisors |
William Hope | Advisor | Board & advisors |
Satoshi Murakami | Advisor | Board & advisors |
Atsushi Usami | Executive Director | Board & advisors |
George Drusano | Advisor | Board & advisors |
Michail Sitkovsky | Advisor | Board & advisors |
Manmeet Singh Ahluwalia | Advisor | Board & advisors |
Samba Siva Reddy V | Principal Scientist | Team |
Rajesh Kumar R. | Senior Scientist | Team |
rashmi naik | Associate Research Scientist | Team |
SWETHA S | Research Scientist | Team |
7 more people are available in the full profile.
Complete people profiles for Bugworks Research
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Bugworks Research
Figures of Bugworks Research India Private Limited, the primary company behind Bugworks Research, for FY 2025. Revenue was ₹25.18 Cr (-12% year on year). Net profit was ₹2.46 Cr (10% margin). EBITDA was ₹3.80 Cr (15% margin). Revenue has grown at a compounded annual rate of +8% over three years and +13% over five years.
- ₹25.18 CrRevenue · FY 2025 · -12% YoY
- ₹2.46 CrNet profit · 10% margin
- ₹3.80 CrEBITDA · 15% margin
- ₹1 LakhPaid-up capital
- 30Employees (provident fund records)
- +8%Revenue CAGR, 3 years
- +13%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Bugworks Research India Private Limited are on its company page.
Detailed financial statements for Bugworks Research
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Bugworks Research
3 dated milestones of Bugworks Research across 14 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round.
- Founded Bugworks Research is founded.
- Funding Latest funding round, Series B, of $6.8M.
Competitors of Bugworks Research
Bugworks Research has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Bugworks Research
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bugworks Research
The website of Bugworks Research (bugworksresearch.com) receives about 9.6K visits a month.
- Monthly visits9.6K
▲ 14.5% vs previous month
Top companies in Infectious Diseases
3 companies that operate in the same segment as Bugworks Research (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bugworks Research
Complete news archive for Bugworks Research
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bugworks Research
Bugworks Research was founded in 2014.
Bugworks Research is headquartered in Saratoga, United States. It is registered at Saratoga, California, United States.
Anand Anandkumar is the CEO of Bugworks Research, as recorded in our data. They have also founded this company.
Bugworks Research is a funded company, having raised a total of $42.89M across 15 funding rounds to date. The company's 1st funding round was a Seed of $1.61M, raised on Jun 2010.
The primary company behind Bugworks Research, Bugworks Research India Private Limited, reported revenue of ₹25.18 Cr for FY 2025, down 12% year on year.
Bugworks Research was founded in 2014 in Saratoga, United States, within the biotechnology sector. Therapeutics targeting antibiotic-resistant bacterial infections and cancer are developed using the Microbial Platform (BMP), which models biofilm formation and bacterial behavior. A lead Gyrase-topoisomerase inhibitor is advanced for intravenous and oral treatments of multi-drug resistant infections, with mechanisms that inhibit two replication targets and circumvent bacterial efflux resistance.
Bugworks Research's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Bugworks Research offers Antibacterial Agents and Oncology Therapeutics.
Bugworks Research has 20 investors. Key investors include NIH, Baxter, 3one4 Capital, CARB-X, and UK Research and Innovation.
Bugworks Research operates through Bugworks Research India Private Limited.
The legal entities of Bugworks Research currently have 3 directors, including Balasubramanian Venkataraman, Vasanthi Ramachandran, Shahul Hameed Peer Mohamed.